NIZO food research BV
Ede, ZB, 6718, Netherlands
NCT Number: NCT05403398
The current study aims to explore a range of possible pathways by which BSCU1 could beneficially modulate the immune system, in three target populations representing the general population.
Looking for future studies?
Notify Me3 year–79 year
All sexes
Interventional
Not applicable
Ede, ZB, 6718, Netherlands
This exploratory study is designed as a single-arm study with repeated measures, involving three different populations, in which each subject serves as its own control. The duration of the intervention is 4 weeks, with biomarker assessments at baseline, after 2 weeks, and after 4 weeks intervention.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Adults
Elderly
Children
Exclusion criteria
Adults and elderly
Children
2 billion CFUs daily, for 4 weeks
Other names: B. subtilis CNCM I-2745
Time frame: 4 weeks
Change in fecal sIgA concentration
Time frame: 4 weeks
Change in serum cytokines concentration (e.g. MIP-1α, IL-6, Il-10, IFN-γ, TNF-α, IL-1β) in elderly using a commercial Multiplex Bead Immunoassay (Bio-Rad, Veenendaal, The Netherlands)
Time frame: 4 weeks
Change in control and Lipopolysaccharide (LPS) stimulated cytokine (e.g. MIP-1α, IL-6, Il-10, IFN-γ, TNF-α, IL-1β) production in whole blood in adults and elderly using a commercial Multiplex Bead Immunoassay (Bio-Rad, Veenendaal, The Netherlands)
Time frame: 4 weeks
Ex-vivo phagocytic function of monocytes and granulocytes using the commercial pHrodo, BioParticles phagocytosis assay kit (Invitrogen, ThermoFisher) for flow cytometry
Time frame: 4 weeks
Fecal microbiota composition using shotgun metagenomics sequencing
Time frame: 4 weeks
Gene expression in PBMC (RNA sequencing)
Time frame: 4 weeks
Immune cell phenotyping will be performed by labelling of the cell with cell specific markers and measured by means of flow cytometry. Two panels of each 8-12 markers will be used for general cell phenotyping, including activation markers, and T cell specific phenotyping in PBMCs.
Lesaffre International
Industry
Change in Markers of Immune Function Associated With Bacillus Subtilis CU1 Intervention in Different Age Groups
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05336604
General Population
Le Kremlin-Bicêtre, France
View Trial DetailsNCT05530720
General Population
Bamberg, Germany
View Trial DetailsNCT04551638
General Population
Barcelona, Catalonia, Spain
View Trial DetailsNCT05338372
General Population
Berlin, Germany
View Trial Details